Pay in 4 interest-free payments of $6.76 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
Huang W, OHara SE, Xie C, Liu N, Rayner CK, Nicholas LM, et al
The most common reasons include: Gastrointestinal side effects such as nausea, vomiting and diarrhea which are the single most frequently documented reason for stopping in large health system datasets High out of pocket cost and lack of insurance coverage particularly in individuals without diabetes Medication unavailability or pharmacy supply shortages which peaked in 2023early 2024 Perceived completion of therapy once target weight is reached or weight loss plateaus Concerns about long term safety or treatment burden of injections Many cohorts show substantial discontinuation by 3 months, with further losses by 6-9 months
For instance, the co-administration of acyl-GIP and acyl-GLP-1 decreased body weight, food intake and fat mass to a greater degree than administration of either of the agonists alone [74]
What other habits set apart newer GLP-1 users from those who have been on the medication for a longer period of time
The drug has a short half-life and needs to be administered by subcutaneous injection three times a day
US$ 20.50
US$ 22.80
US$ 26.09
US$ 26.20
US$ 23.58
US$ 20.40
US$ 21.35
